ATE327740T1 - Verwendung von acetylcholinesterasen hemmern zur herstellung eines arzneimittels zur behandlung von funktionellen und/oder organischen schmerzsyndromen - Google Patents

Verwendung von acetylcholinesterasen hemmern zur herstellung eines arzneimittels zur behandlung von funktionellen und/oder organischen schmerzsyndromen

Info

Publication number
ATE327740T1
ATE327740T1 AT99946150T AT99946150T ATE327740T1 AT E327740 T1 ATE327740 T1 AT E327740T1 AT 99946150 T AT99946150 T AT 99946150T AT 99946150 T AT99946150 T AT 99946150T AT E327740 T1 ATE327740 T1 AT E327740T1
Authority
AT
Austria
Prior art keywords
treatment
functional
production
pain syndrome
medicinal product
Prior art date
Application number
AT99946150T
Other languages
English (en)
Inventor
Maria Nicolodi
Federigo Sicuteri
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of ATE327740T1 publication Critical patent/ATE327740T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT99946150T 1998-09-11 1999-09-09 Verwendung von acetylcholinesterasen hemmern zur herstellung eines arzneimittels zur behandlung von funktionellen und/oder organischen schmerzsyndromen ATE327740T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT1998FI000208A IT1304904B1 (it) 1998-09-11 1998-09-11 Derivati anticolinesterasici per il trattamento delle sindromidolorose funzionali e/o organiche

Publications (1)

Publication Number Publication Date
ATE327740T1 true ATE327740T1 (de) 2006-06-15

Family

ID=11352669

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99946150T ATE327740T1 (de) 1998-09-11 1999-09-09 Verwendung von acetylcholinesterasen hemmern zur herstellung eines arzneimittels zur behandlung von funktionellen und/oder organischen schmerzsyndromen

Country Status (12)

Country Link
US (1) US6608088B1 (de)
EP (1) EP1112067B1 (de)
JP (1) JP3984787B2 (de)
AT (1) ATE327740T1 (de)
AU (1) AU5861799A (de)
CY (1) CY1105125T1 (de)
DE (1) DE69931640T2 (de)
DK (1) DK1112067T3 (de)
ES (1) ES2265691T3 (de)
IT (1) IT1304904B1 (de)
PT (1) PT1112067E (de)
WO (1) WO2000015205A2 (de)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2133078A1 (de) 2000-03-03 2009-12-16 Eisai R&D Management Co., Ltd. Verwendung eines Cholinesterase-Hemmers für die Behandlung von kognitiven Beeinträchtigungen und/oder Demenz, die mit Gehirntumoren in Zusammenhang gebracht oder davon verursacht wird
US20060183776A9 (en) * 2000-03-03 2006-08-17 Eisai Co., Ltd. Liquid dosage formulations of donepezil
NZ522115A (en) * 2000-04-21 2004-07-30 Upjohn Co Selected compounds for the treatment of fibromyalgia and chronic fatigue syndrome
WO2002083141A1 (en) * 2001-04-17 2002-10-24 Pharmacia & Upjohn Company Treatment of fibromyalgia and chronic fatigue syndrome
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
BRPI0606110A2 (pt) * 2005-01-25 2009-06-02 Epix Delaware Inc compostos de arilamina substituìdos e seu uso como 5 - ht6 moduladores
EP1881756B1 (de) * 2005-02-11 2016-08-10 Stephen Wills Behandlung von krankheiten des mikrovaskulären systems mit acetylcholinesterase-inhibitoren
US20090131480A1 (en) * 2005-04-04 2009-05-21 Eisai Co., Ltd. Dihydropyridine Compounds for Neurodegenerative Diseases and Dementia
JP2009541368A (ja) * 2006-07-05 2009-11-26 天津和美生物技▲術▼有限公司 鎮痛性５，９−メタノシクロオクタ（ｂ）ピリジン−２−（１Ｈ）−オン誘導体、その作成方法と用途
US8012994B1 (en) 2006-09-22 2011-09-06 Sevastyanov Victor V Method for the treatment of sensorineural hearing loss with donepezil hydrochloride (ARICEPT®)
US8278345B2 (en) 2006-11-09 2012-10-02 Probiodrug Ag Inhibitors of glutaminyl cyclase
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
JP5930573B2 (ja) 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
WO2009126931A2 (en) 2008-04-11 2009-10-15 Xvasive, Inc. Combination therapy for bipolar disorder
PL2475428T3 (pl) 2009-09-11 2015-12-31 Probiodrug Ag Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej
EA037187B1 (ru) 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Способ и композиция для лечения когнитивного расстройства
EP2542549B1 (de) 2010-03-03 2016-05-11 Probiodrug AG Glutaminylcyclase-hemmer
US8269019B2 (en) 2010-03-10 2012-09-18 Probiodrug Ag Inhibitors
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
US8530670B2 (en) 2011-03-16 2013-09-10 Probiodrug Ag Inhibitors
JP2015078129A (ja) * 2012-02-01 2015-04-23 株式会社新日本科学 ドネペジルを含む線維筋痛症の治療剤
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
MX384391B (es) 2015-05-22 2025-03-14 Agenebio Inc Composiciones farmacéuticas de levetiracetam de liberación extendida.
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5010083A (en) * 1988-03-28 1991-04-23 Hoechst-Roussel Pharmaceuticals, Inc. 2,6-methano-1,3-benzodiazocine compounds which have useful pharmaceutical utility
DE3927049A1 (de) * 1989-08-16 1991-02-21 Sandoz Ag Halogenalkyl-phenyl-ketone und deren hydrate, ihre herstellung und verwendung
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
GB9606736D0 (en) 1996-02-19 1996-06-05 Shire International Licensing Therapeutic method
AU8742198A (en) 1997-08-15 1999-03-08 Shire International Licensing B.V. Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity

Also Published As

Publication number Publication date
ITFI980208A1 (it) 2000-03-11
CY1105125T1 (el) 2009-11-04
US6608088B1 (en) 2003-08-19
AU5861799A (en) 2000-04-03
DE69931640T2 (de) 2007-03-08
JP3984787B2 (ja) 2007-10-03
IT1304904B1 (it) 2001-04-05
DK1112067T3 (da) 2006-09-04
PT1112067E (pt) 2006-09-29
ITFI980208A0 (it) 1998-09-11
ES2265691T3 (es) 2007-02-16
WO2000015205A2 (en) 2000-03-23
DE69931640D1 (de) 2006-07-06
JP2002524498A (ja) 2002-08-06
WO2000015205A3 (en) 2000-08-24
EP1112067B1 (de) 2006-05-31
EP1112067A2 (de) 2001-07-04

Similar Documents

Publication Publication Date Title
ATE327740T1 (de) Verwendung von acetylcholinesterasen hemmern zur herstellung eines arzneimittels zur behandlung von funktionellen und/oder organischen schmerzsyndromen
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
DK0801564T3 (da) Anvendelse af nebivolol som et antiatherogent middel
DE69523745D1 (de) Gel zur behandlung von hauterkrankungen und zur desinfizierung von haut
DE69805202D1 (de) Verwendung von benzhydrylsulfinylderivaten zur behandlung der schläfigkeit medikamentösen ursprungs
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
DE69827651D1 (de) Verwendung von tempol zur behandlung von essentiellem hochdruck
ATE218350T1 (de) Verwendung von methanbisphosphonsäurederivaten zur behandlung von aufgelockerten prothesen
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
DE69713620D1 (de) Verwendung von arachidonsäure und/oder docohexaensäure zur herstellung eines arzneimittels zur behandlung von dyspraxia
DE69825286D1 (de) Verwendung von cholinesterasehemmern zur behandlung von aufmerksamkeitsmangel-störungen
DE69911380D1 (de) Verwendung von isatin- und oxindolderivaten zur herstellung von arzeneimittel für die behandlung von mykobakteriellen erkrankungen
ATE318141T1 (de) Verwendung von taurolidin oder taurultam zur herstellung eines arzneimittels zur vorbeugung von metastasen
DE69825440D1 (de) VERWENDUNG VON TAUROLIDINE ZUR Herstellung eines Arzneimittels zur BEHANDLUNG VON LEUKÄMIEN
BR9917495A (pt) Derivados o ácido betulìnico tendo atividade antiangiogênica, processos para produzir tais derivados e sua utilização para o tratamento de antiogênese associada a tumores
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
ATE214605T1 (de) Verwendung von eliprodil zur herstellung eines arzneimittels zur behandlung von ischämischen störungen der retina oder des sehnervs
ATE192929T1 (de) Verwendung von dimeticon zur herstellung eines arzneimittels zur behandlung von aphthen und stomatitis
ATE247956T1 (de) Verwendung von modafinil zur herstellung eines arzneimittels zur behandlung von vigilanzstörungen im zusammenhang mit myopathien
ATE234613T1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
DE69919578D1 (de) VERWENDUNG von NIEDERMOLEKULAREM HEPARIN zur Behandlung und/oder Prophylaxe motoneuronaler Krankheiten
ATE275949T1 (de) Verwendung von diminazen-di-aceturat und/oder pentamidin zur behandlung von malaria
DE50012667D1 (de) Verwendung von 2-amino-3,4-dihydro-chinazolinen zur herstellung eines medikaments zur behandlung oder prophylaxe von ischämischen zuständen
ATE275420T1 (de) Verwendung von cysteinprotease inhibitoren zur herstellung eines arzneimittels zur vorgbeugung und behandlung von gehirngewebezerrütung infolge hypertensive enzephalopathie oder encephalothlipsis

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1112067

Country of ref document: EP

EEIH Change in the person of patent owner